Introduction
============

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus (DM). Due to the enormous cardiovascular (CV) burden associated with DM, reduction in CV risk is one of the main goals in the treatment of DM. In 2012, the cost of the treatment of DM was estimated to be \>245 billion dollars a year in the USA alone, representing the biggest economic burden to the US health-care system, with a large portion spent on the treatment of CV complications.[@b1-pgpm-11-071]

The increased risk of CVD in patients with DM is partially due to increased oxidative stress mediated by the generation of reactive oxygen species in hyperglycemic states leading to oxidative modifications of low-density lipoprotein (LDL), high-density lipoprotein (HDL) and various proteins within the vessel wall, thus increasing their thermogenic potential.[@b2-pgpm-11-071],[@b3-pgpm-11-071] One of the major consequences of these oxidative modifications is that HDL can lose its protective anti-inflammatory properties as well as the ability to shuttle cholesterol back to the liver through reverse cholesterol transport.

Beyond the traditional risk factors for CVD, genetic susceptibility is a major determinant of CV risk, including patients with DM. One such genetic biomarker is the haplotype for the gene that encodes the haptoglobin (Hp) protein at the chromosome 16q22 locus.[@b4-pgpm-11-071] Hp is an α2-sialoglycoprotein synthesized by hepatocytes to protect blood vessels and the kidneys from adverse oxidative effects and tissue injury induced by extracorpuscular free hemoglobin (Hb) released during intravascular lysis of erythrocytes amounting to several grams of free Hb each day.[@b5-pgpm-11-071]--[@b7-pgpm-11-071] There are two major common classes of alleles for this gene, Hp 1 and Hp 2, with the Hp 2 allele probably arising from a duplication event of exons 3 and 4 of the Hp 1 allele early in human evolution.[@b4-pgpm-11-071] In the Western world, in both healthy and patients with DM, the genotype frequency of Hp 1-1, Hp 1-2 and Hp 2-2 is 16%, 48% and 36%, respectively.[@b8-pgpm-11-071],[@b9-pgpm-11-071] Previous studies have shown that Hp 2-2 protein is an inferior antioxidant compared with other Hp proteins with a resultant increase in Hb-driven lipoprotein oxidative modifications, HDL dysfunction, increased macrophage inflammation and apoptosis, thus leading to increased atherogenicity, specifically in the setting of DM.[@b10-pgpm-11-071]--[@b15-pgpm-11-071] The increased oxidative stress seen in both in vitro and in vivo patients with DM and the Hp 2-2 genotype suggests antioxidants as a potential target for mitigating CVD risk among this group. Vitamin E administration is a potential treatment that could provide an affordable, accessible and effective benefit to patients with high oxidative stresses on their CV system. Vitamin E is a group of eight lipophilic molecules, α-, β-, γ- and δ-tocopherol and α-, β-, γ- and δ-tocotrienol, which acts as antioxidants by scavenging free radicals and singlet oxygen.[@b16-pgpm-11-071],[@b17-pgpm-11-071] Despite encouraging preclinical data, early clinical trials failed to show a benefit of vitamin E supplementation on preventing CVD.[@b18-pgpm-11-071] It is possible that this was due to a failure to identify specific patient populations with increased oxidative stress that would benefit from vitamin E therapy.

Multiple clinical studies have investigated the effect of Hp genotype on CV clinical outcomes with most, but not all, showing an increased incidence of CV events and CV death among patients with DM and the Hp 2-2 genotype. This study has two main aims. First, we sought to compile and summarize the data from all of the published clinical trials related to the incidence of CV events in patients with DM, according to their Hp genotype. This includes data from 13 trials that looked at multiple outcomes, including myocardial infarction (MI), stroke, CV death and end-stage renal disease (ESRD). Second, we sought to compile and assess all of the data on the clinical benefit of vitamin E treatment among patients with DM based on their Hp genotype.

Methods
=======

Search strategy
---------------

The electronic databases MEDLINE, PubMed, Embase and the Cochrane Library for Central Register of Clinical Trials were searched systematically using the following MESH terms: "haptoglobin 2-2 genotype", "diabetes mellitus" and "cardiovascular events". The search was limited to the studies in human subjects and peer-reviewed journals in English language published until February 2017. The two reviewers identified a total of 530 studies, after the independent electronic search. There were no disagreements in the literature search between the reviewers. Subsequently, the references listed in the 13 studies identified by the electronic search were manually searched. Manual search did not reveal any new studies apart from the ones identified by the electronic search.

Study selection
---------------

All observational studies published as original articles in peer-reviewed scientific journals in English were included. Studies were selected based on inclusion criteria: patient population: group of patients with DM (type 1 or type 2) in accordance with the standard clinical guidelines, use of Hp genotyping or phenotyping and comparison of outcomes between patients with and without the Hp 2-2 genotype. In the subgroup analysis of prospective randomized controlled trials (RCTs), vitamin E was administered in patients with type 2 DM and the Hp 2-2 genotype. Those trials that did not report any of the following variables or outcomes: number of events in both the intervention and reference groups, length of study, description of the main relevant features of the study population, including gender and age, were excluded. The eligibility was not restricted according to the outcomes.

Data extraction and quality
---------------------------

The data were independently extracted by two authors (R.A. and A.B.) using the standardized protocol and reporting form. Disagreements were resolved by open discussion, and consensus was reached after discussion.

The study characteristics such as study design, sample size, baseline demographics and CV risk factors, inclusion criteria and exclusion criteria, primary and secondary outcomes and follow-up duration and demographic characteristics of the patients were extracted.

Outcome assessment
------------------

The primary outcome measure was incident CV events, including fatal and nonfatal MI, stroke, heart failure and need for revascularization. Death or all-cause mortality, MI, CV death, stroke and ESRD were also examined. Four studies included MI (Heart Outcomes Prevention Evaluation \[HOPE\] double placebo, Israeli Cardiovascular Vitamin E \[ICARE\], Women's Health Study \[WHS\] and MUNICH post-PCA), two studies included all-cause mortality (Diabetes Heart Study \[DHS\] and WHS), two studies included ESRD (Diabetes Control and Complications Trial \[DCCT\] and Epidemiology of Diabetes Complications \[EDC\]), three studies included stroke (HOPE double placebo, ICARE and WHS) and five studies included CV death (HOPE double placebo, ICARE, WHS, DHS and MUNICH post-PCA) as part of their outcomes.

Risk of bias
------------

The Cochrane's risk of bias tool was utilized in order to assess the individual risk of bias of each RCT. The Newcastle--Ottawa tool was used for the quality assessment of cohort studies. Two authors independently assessed the risk of bias and quality of studies in each eligible trial. This scale appoints a maximum of nine stars to each study: four stars for the adequate selection of the two groups, two stars for comparability of groups on the basis of the design and analysis and three stars for the adequate ascertainment of the exposure in both groups. High-quality studies received nine stars and medium-quality studies seven or eight stars.

Data analysis and synthesis
---------------------------

An intention-to-treat traditional meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. All analyses were performed by Review Manager (RevMan) 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). The *χ*^2^ test of heterogeneity and the *I*^2^ statistic of inconsistency were used to assess heterogeneity between studies. Statistically significant heterogeneity was defined as a *χ*^2^ *P*-value \<0.05 or an *I*^2^ statistic \>75%. In the absence of heterogeneity, pooled estimates of relative risks with their 95% CIs were calculated using the Mantel--Haenszel method. A DerSimonian--Laird random effects model for OR estimation for all outcomes was used in the presence of heterogeneity. Reported values are two-tailed, and hypothesis testing results were considered statistically significant when *P*\<0.05. Small study effect, including publication bias, was tested using the funnel plot and the Egger's test. If publication bias was found, the nonparametric trim and fill method of Duval and Tweedie was performed to add studies that appeared to be missing.

Results
=======

Study selection
---------------

Our search strategy is outlined in [Figure 1](#f1-pgpm-11-071){ref-type="fig"}. Literature search resulted in a total of 13 studies including three prospective RCTs, three case--control and seven cohort studies, which were analyzed separately for each outcome. All of them were reported between 2000 and 2016. For the end point of CV events, subgroup analysis was performed for RCTs, cohort and case--control studies. Additionally, the effects of vitamin E on CV events in patients with and without the Hp 2-2 genotype were analyzed.

Study characteristics
---------------------

The total number of patients without Hp 2-2 was 6,161 and with Hp 2-2 was 4,684. The baseline characteristics of the included studies are represented in [Table 1](#t1-pgpm-11-071){ref-type="table"}. Among Hp 2-2 patients included in the analysis of the three RCTs, 1,094 were randomized to receive vitamin E supplementation and 1,016 to receive placebo.

Quality assessment
------------------

On the basis of quality assessment, all studies were deemed to be high quality. No low-quality studies were included.

CV events
---------

Eleven studies reported data on CV events (CVD events). The incidence of CVD events in DM patients with the Hp 2-2 genotype was significantly increased as compared to patients without the Hp 2-2 genotype in all three subgroups of case--control studies (OR: 2.18, 95% CI: 1.31--3.61, *P*=0.003; [Figure 2A](#f2-pgpm-11-071){ref-type="fig"}), in cohort studies (OR: 1.31, 95% CI: 1.12--1.55; *P*=0.001; [Figure 2A](#f2-pgpm-11-071){ref-type="fig"}) and in RCTs (OR: 1.60, 95% CI: 1.15--2.22; *P*=0.005; [Figure 2A](#f2-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.37; *I*^2^=46.7%, *P*=0.38; and *I*^2^=26.36%, *P*=0.26, respectively). Among patients with the Hp 2-2 genotype, administration of vitamin E was associated with lower rates of CVD events (OR: 0.66, 95% CI: 0.45--0.95; *P*=0.025; [Figure 2B](#f2-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=16.16%, *P*=0.30). Among non-Hp 2-2 patients, administration of vitamin E did not significantly affect the rates of CVD events compared with placebo (OR: 1.11, 95% CI: 0.80--1.53, *P*=0.50; [Figure 2C](#f2-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.45).

Myocardial infarction
---------------------

Five studies reported data on the incidence of MI: three RCTs (ICARE, WHS and HOPE) and two cohort studies (DCCT/ Epidemiology of Diabetes Interventions and Complications and MUNICH post-PCA). MI rates were significantly increased in patients with Hp 2-2 in both the RCT subgroup (OR: 1.45, 95% CI: 1.01--2.07, *P*=0.043; [Figure 3A](#f3-pgpm-11-071){ref-type="fig"}) and cohort studies (OR: 1.86, 95% CI: 1.19--2.90, *P*=0.006; [Figure 3A](#f3-pgpm-11-071){ref-type="fig"}) without significant heterogeneity between trials (*I*^2^=0%, *P*=0.53 and *I*^2^=36.68%, *P*=0.21, respectively). Vitamin E administration was associated with numerically lower but not statistically significant rates of MI in patients with the Hp 2-2 genotype (OR: 0.62, 95% CI: 0.35--1.11, *P*=0.10; *I*^2^=39.34%, *P*=0.19; [Figure 3B](#f3-pgpm-11-071){ref-type="fig"}).

Mortality
---------

Two studies reported data on the incidence of all-cause mortality (DHS and WHS) and four studies on CV mortality (DHS, WHS, ICARE and HOPE). The presence of Hp 2-2 genotype was not associated with higher all-cause mortality (OR: 1.19, 95% CI: 0.93--1.52; *P*=0.17; [Figure 4](#f4-pgpm-11-071){ref-type="fig"}). CV death rates were not significantly different among patients with the Hp 2-2 genotype compared with patients carrying other genotypes in the RCT subgroup (OR: 2.17, 95% CI: 0.71--6.68; *P*=0.18; [Figure 5A](#f5-pgpm-11-071){ref-type="fig"}), with significant heterogeneity between studies (*I*^2^=68.43%, *P*=0.042). However, supplementation of vitamin E resulted in significantly lower rates of CV death among patients with Hp 2-2 (OR: 0.47, 95% CI: 0.26--0.85; *P*=0.013; [Figure 5B](#f5-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.93).

Stroke
------

Three RCTs reported data on the incidence of stroke (WHS, ICARE and HOPE). The presence of Hp 2-2 genotype was not associated with higher incidence of stroke (OR: 1.48, 95% CI: 0.95--2.30; *P*=0.085; [Figure 6A](#f6-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.47). Supplementation of vitamin E did not significantly decrease rates of stroke among patients with the Hp 2-2 genotype (OR: 0.78, 95% CI: 0.44--1.37; *P*=0.39; [Figure 6B](#f6-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.47).

End-stage renal disease
-----------------------

Two studies reported data on the incidence of ESRD (DCCT and Epidemiology of Diabetes Complications). The ESRD rates were significantly increased in patients with the Hp 2-2 genotype (OR: 1.66, 95% CI: 1.04--2.64; *P*=0.03; [Figure 7](#f7-pgpm-11-071){ref-type="fig"}), without significant heterogeneity between trials (*I*^2^=0%, *P*=0.56).

Publication bias
----------------

The funnel plot did not show asymmetry consistent with publication bias, and the Egger's test was not significant for the outcomes studied.

Discussion
==========

Despite the importance of the common Hp copy number variant polymorphism, which determines Hp structure and affects its function, the relationship of copy number variant with genome-wide association is challenging.[@b19-pgpm-11-071] The reason for this complex association is that there is no strong linkage disequilibrium with any individual single nucleotide polymorphism (SNP) to allow one to successfully determine the Hp genotype with array-based copy number analysis or low-coverage sequencing.[@b19-pgpm-11-071]--[@b21-pgpm-11-071] Therefore, Hp typing for each individual remains possible only with serum protein electrophoresis[@b22-pgpm-11-071] or polymerase chain reaction,[@b23-pgpm-11-071],[@b24-pgpm-11-071] which restricts the size and power of clinical studies to demonstrate association with clinical outcomes. In this systematic review and meta-analysis, the results of relevant association studies in the literature were pooled to provide strong evidence that the Hp 2-2 genotype is associated with increased risk of CV disease among patients with DM as compared to those with other Hp genotypes. The results of the RCTs also demonstrate that vitamin E administration provides significant clinical benefit to DM patients with the Hp 2-2 genotype. Although there was no significant difference in CV mortality between Hp patient groups, vitamin E administration resulted in a significant decrease in CV mortality and the composite of CV events in the Hp 2-2 DM cohort, whereas no such benefit was seen with vitamin E therapy in the non-Hp 2-2 cohort. These results illustrate the potential benefit of selective vitamin E administration for the reduction of CV adverse clinical outcomes among DM patients with the Hp 2-2 genotype.

Although no significant relationship between Hp 2-2 haplotype and stroke was found in this study, previous studies have noted significant associations between the Hp genotype and stroke. One study found that the Hp 2 allele was associated with ischemic stroke in the general population.[@b25-pgpm-11-071] Furthermore, a retrospective analysis of the Helsinki Stroke Aging Memory trial of 378 patients who previously experienced a stroke showed that the combined risk of ischemic CV death was 2.4-fold higher among patients with at least one Hp 2 allele but only showed a nonsignificant trend toward an association with subsequent ischemic strokes.[@b26-pgpm-11-071] Interestingly, another study found that the Hp 1-1 haplotype was associated with lacunar stroke in young patients lacking silent lacunar infarcts or extensive white matter lesions.[@b27-pgpm-11-071] Likewise, a prospective study found an association between the Hp 1-1 haplotype and an increased risk of stroke in type 1 diabetic patients.[@b28-pgpm-11-071] These studies highlight that the relationship between the Hp genotype and risk of stroke might be different from coronary artery disease.

It remains to be seen whether other antioxidants may provide protection. The WAVE study showed that vitamin C added to vitamin E therapy had a detrimental effect in postmenopausal Hp 2-2 DM women as they displayed a marked decrease in luminal diameter as compared to those who received placebo.[@b29-pgpm-11-071] Preclinical studies have also demonstrated that adding vitamin C to vitamin E mitigates the protective effect of vitamin E on atherosclerotic plaque development.[@b30-pgpm-11-071],[@b50-pgpm-11-071] When combined with the results of other studies, this indicates that vitamin E antioxidant therapy may provide superior benefit to this patient group and that other antioxidant therapies may actually be detrimental.

This analysis is limited for certain subgroups and CVD disorders. While the trends are consistent with those seen in type 2 DM for coronary disease, only two studies have examined this relationship in type 1 DM and/or using ESRD end point outcomes. Previously, a mechanism to explain how the Hp 2-2 genotype causes an increased risk of CV events was proposed. On the basis of preclinical and clinical data, it has been proposed that the increased risk of CV events associated with the Hp 2-2 genotype is due to the Hp 2 polymers causing HDL to become dysfunctional and pro-atherogenic. HDL normally functions to protect against CVD by serving as an antioxidant, modulating inflammation by preventing the production of oxidized low-density lipoprotein and facilitating reverse cholesterol transport.[@b31-pgpm-11-071],[@b32-pgpm-11-071] The serum from DM patients with the Hp 2-2 genotype has been shown to have a decreased ability to mediate reverse cholesterol transport compared to DM patients with Hp 1-1.[@b13-pgpm-11-071] It has been suggested that this is due to a synergy between Hp 2-2 and DM causing downregulation of the Hb scavenging receptor, CD163, on macrophages and monocytes, thereby resulting in the delayed clearance of the Hp--Hb complexes in DM patients with the Hp 2-2 genotype.[@b14-pgpm-11-071],[@b33-pgpm-11-071] As Hp can bind to ApoA1, this results in an increased amount of Hp-Hb being associated with HDL in DM patients with the Hp 2-2 genotype ([Figure 8](#f8-pgpm-11-071){ref-type="fig"}). The binding of Hb to HDL results in oxidative modification of HDL, a process that is mediated by the ability of iron to generate free radicals via the Fenton reaction leading to lipoprotein peroxidation. The increased iron also leads to more nitrous oxide scavenging and decomposition leading to decreased signaling. Furthermore, this causes endothelial injury and dysfunction, platelet aggregation, inflammation and increased thermogenesis, all of which lead to an increased risk of CV events.

The differential effect of vitamin E on adverse CV outcomes may be explained by differences in the underlying oxidative stress burden in DM patients with different Hp genotypes. Studies have shown that vitamin E acts as a potent antioxidant due to its capability of scavenging free radicals and blocking oxidative reactions.[@b16-pgpm-11-071],[@b17-pgpm-11-071] In DM patients with the Hp 2-2 genotype, vitamin E administration can reverse the deleterious cascade driven by high oxidative stress in this group by balancing this increased oxidative burden thus mitigating CV risk. Low level of oxidative stress is still required to maintain normal hemostasis and metabolic function and is also crucial for facilitating various biological processes, such as its involvement in host defense against pathogens. Among patients with low oxidative stress, abolishing this protective manner of oxidation required for maintaining stability may be harmful. By disturbing the balance between pro-oxidants and antioxidants in patients with low oxidative stress, vitamin E administration may increase the risk of adverse outcomes in patients with non-Hp 2-2 genotypes who generally have low levels of oxidative stress.

The mechanisms underlying the association of the Hp 2-2 genotype with increased risk of renal failure are less understood. Oxidative stress has been shown to play a role in renal injury. Studies have shown that iron accumulation within lysosomes of the renal proximal tubules are increased in diabetic animal models with the Hp 2-2 genotype compared with those with other Hp genotypes, leading to poor lysosomal integrity and cell injury.[@b34-pgpm-11-071],[@b51-pgpm-11-071] Using renal quantitative T2\* MRI in patients with type 1 DM, Costacou et al[@b35-pgpm-11-071] have recently shown that kidney iron deposition is significantly increased among patients with the Hp 2-2 genotype and albuminuria.

This study has several limitations. First, given the small number of available studies on this topic in the literature, the data from studies that differ in design, clinical endpoints and length of follow-up had been included. Second, the limited number of RCTs could be underpowered to show significant increase in the risk of stroke in DM patients with the Hp 2-2 genotype or to show a significant decrease in the risk of MI with vitamin E administration in the same population. Moreover, these RCTs did not initially aim to examine the Hp genotype, and thus the data were retrospectively analyzed. However, despite the limited number and differences between the included studies, baseline characteristics were similar, and the combined study cohorts allowed us to identify significant associations with several CV outcomes that are of great clinical relevance to the DM population. Finally, although attempts were made to include all journal articles matching the stated inclusion criteria, it is still possible that this analysis was subject to publication bias.

Conclusion
==========

Globally, the number of patients with DM has increased dramatically since 1980, and the World Health Organization estimated that the prevalence has nearly doubled to 8.5%.[@b1-pgpm-11-071] A majority of DM patients have type 2 DM and \~36% of them have the Hp 2-2 genotype.[@b8-pgpm-11-071],[@b9-pgpm-11-071] Thus, treatment targeting the increased incidence of CV events and increased CV mortality in DM patients with the Hp 2-2 genotype has significant potential. Administration of vitamin E offers a low cost means of reducing CV events in this population. Although it is unlikely that pharmaceutical companies will evaluate vitamin E as a potential treatment option, additional large-scale clinical trials should be pursued to evaluate its efficacy in reducing CV burden among a substantial portion of DM patients with genetically driven high oxidative stress and susceptibility to CV events.
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![Search strategy for studies used in our meta-analysis.](pgpm-11-071Fig1){#f1-pgpm-11-071}

![Hp 2-2 genotype and risk of CV events and effect of vitamin E on major CV outcomes.\
**Notes:** (**A**) Random effect meta-analysis of cohort studies and RCTs for CV events between Hp 2-2 and non-Hp 2-2 genotypes. The figure presents number of events, number of patients in treatment and control groups, OR and 95% CI for each trial, overall OR estimate with 95% CI and *P* value for association test, *P* value for heterogeneity test and between trial inconsistency (*I*^2^) measures. (**B**) Random effect meta-analysis of the effects of vitamin E administration on CV events in diabetic patients with the Hp 2-2 genotype. (**C**) Random effect meta-analysis of the effects of vitamin E administration on CV events in diabetic patients without the Hp 2-2 genotype.\
**Abbreviations:** CV, cardiovascular; DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study; DHS, Diabetes Heart Study; EDC, Epidemiology of Diabetes Complications; HOPE, Heart Outcomes Prevention Evaluation; Hp, haptoglobin; HPFS, Health Professionals Followup Study; ICARE, Israeli Cardiovascular Vitamin E; NHS, Nurses' Health Study; RCT, randomized controlled trial; SHS, Strong Heart Study; WHS, Women's Health Study.](pgpm-11-071Fig2){#f2-pgpm-11-071}

![Hp 2-2 genotype and risk of MI and effect of vitamin E on MI risk.\
**Notes:** (**A**) Random effect meta-analysis of cohort studies and RCTs for MI between Hp 2-2 and non-Hp 2-2 genotypes. (**B**) Random effect meta-analysis of the effects of vitamin E administration on MI in diabetic patients with the Hp 2-2 genotype.\
**Abbreviations:** DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study; HOPE, Heart Outcomes Prevention Evaluation; Hp, haptoglobin; ICARE, Israeli Cardiovascular Vitamin E; MI, myocardial infarction; RCT, randomized controlled trial; WHS, Women's Health Study.](pgpm-11-071Fig3){#f3-pgpm-11-071}

![Hp 2-2 genotype and risk of all-cause mortality.\
**Note:** Random effect meta-analysis of cohort studies and RCTs for all-cause mortality between Hp 2-2 and non-Hp 2-2 genotypes.\
**Abbreviations:** DHS, Diabetes Heart Study; Hp, haptoglobin; RCT, randomized controlled trial; WHS, Women's Health Study.](pgpm-11-071Fig4){#f4-pgpm-11-071}

![Hp 2-2 genotype and risk of CV mortality and the effect of vitamin E on CV mortality risk.\
**Notes:** (**A**) Random effect meta-analysis of cohort studies and RCTs for CV mortality between Hp 2-2 and non-Hp 2-2 genotypes. (**B**) Random effect meta-analysis of the effects of vitamin E administration on CV mortality in diabetic patients with the Hp 2-2 genotype.\
**Abbreviations:** CV, cardiovascular; DHS, Diabetes Heart Study; HOPE, Heart Outcomes Prevention Evaluation; Hp, haptoglobin; ICARE, Israeli Cardiovascular Vitamin E; RCT, randomized controlled trial; WHS, Women's Health Study.](pgpm-11-071Fig5){#f5-pgpm-11-071}

![Hp 2-2 genotype and risk of stroke and effect of vitamin E on stroke risk.\
**Notes:** (**A**) Random effect meta-analysis of cohort and randomized controlled studies for stroke between Hp 2-2 and non-Hp 2-2 genotypes. (**B**) Random effect meta-analysis of the effects of vitamin E administration on stroke in diabetic patients with the Hp 2-2 genotype.\
**Abbreviations:** HOPE, Heart Outcomes Prevention Evaluation; Hp, haptoglobin; ICARE, Israeli Cardiovascular Vitamin E; RCT, randomized controlled trial; WHS, Women's Health Study.](pgpm-11-071Fig6){#f6-pgpm-11-071}

![Hp 2-2 genotype and risk of ESRD.\
**Note:** Random effect meta-analysis for ESRD between Hp 2-2 and non-Hp 2-2 genotypes.\
**Abbreviations:** DCCT, Diabetes Control and Complications Trial; EDC, Epidemiology of Diabetes Complications; ESRD, end-stage renal disease; Hp, haptoglobin; RCT, randomized controlled trial.](pgpm-11-071Fig7){#f7-pgpm-11-071}

![Mechanistic explanations of the increased risk of atherosclerosis CVD in patients with the Hp 2-2 genotype and the mechanistic rationale of using vitamin E to reduce CV burden in this cohort.\
**Notes:** Top right image shows an illustration of how the Hp 2-2 genotype in diabetic patients leads to decreased clearance of Hp--Hb complexes due to downregulation of the CD163 receptor. The higher steady state of the cell-free Hp--Hb complexes leads to the generation of ROS via the Fenton reaction subsequently to lipid peroxidation. It also leads to more binding of the Hp 2-2--Hb complexes to HDL and subsequent oxidation of lipoproteins. This renders HDL dysfunction causing increased inflammation, reduced antioxidant ability, reduced RCT, increased atherogenesis and an increased risk of CV events. The bottom right image shows how vitamin E therapy can reverse this cascade by maintaining the balance between antioxidant and ROS and remove the associated risk with the Hp 2-2 genotype. The figures on the left show how vitamin E therapy can cause an increased risk of hypertension, bleeding and increased CVD in DM patients with the non-Hp 2-2 genotype by disturbing the balance of antioxidants and ROS with administration of vitamin E.\
**Abbreviations:** CV, cardiovascular; CVD, cardiovascular disease; Hb, hemoglobin; HDL, high-density lipoprotein; Hp, haptoglobin; LDL, low-density lipoprotein; ROS, reactive oxygen species.](pgpm-11-071Fig8){#f8-pgpm-11-071}

###### 

Interventions and characteristics of individual studies on clinical outcomes in association with Hp genotype and clinical benefit from vitamin E

  Studies                             Year   Design                          Sample size, Hp 2-2/non-Hp 2-2   Age (years)   Male (%)   Clinical characteristics   Outcomes                                                           Vitamin E dose           Quality
  ----------------------------------- ------ ------------------------------- -------------------------------- ------------- ---------- -------------------------- ------------------------------------------------------------------ ------------------------ --------------
  HOPE study[@b36-pgpm-11-071]        2000   Retrospective analysis of RCT   91/187                           66            73.3       T2D                        MI, stroke, CV death and all-cause death                           400 IU daily             High
  SHS[@b37-pgpm-11-071]               2002   Nested case--control            66/173                           60            50.5       T2D American Indians       MI and CV events                                                   N/A                      High
  MUNICH post-PCA[@b38-pgpm-11-071]   2003   Cohort                          382/553                          67.3          71         T2D after PTCA             Death, TVR, MI, repeat PTCA and restenosis                         N/A                      High
  RAMBAM post-MI[@b39-pgpm-11-071]    2005   Cohort                          582/855                          61            79         T2D after MI               30-day mortality and heart failure                                 N/A                      High
  ICARE study[@b40-pgpm-11-071]       2008   Retrospective analysis of RCT   1434/1533                        69            47.7       T2D                        CV death, all-cause death, TVR, MI, stroke and heart failure       400 IU daily             High
  EDC study[@b41-pgpm-11-071]         2008   Cohort                          214/239                          26.9          50.5       T1D                        MI, revascularization, stenosis \>50% or death from CAD            N/A                      High
  EDC-ESRD[@b42-pgpm-11-071]          2009   Cohort                          202/272                          27.5          47         T1D                        Microalbuminuria, decline of ≥30 mL/min in eGFR and ESRD           N/A                      High
  WHS[@b43-pgpm-11-071]               2010   Retrospective analysis of RCT   277/444                          N/A           0          Diabetic females           Nonfatal MI, nonfatal stroke, cardiovascular death, PTCA or CABG   600 IU every other day   Intermediate
  DHS[@b44-pgpm-11-071]               2013   Cohort                          535/673                          61.5          46.8       T2D                        CV mortality and all-cause mortality                               N/A                      High
  DCCT/EDIC[@b45-pgpm-11-071]         2013   Cohort                          516/787                          27            52         T1D                        Albuminuria, eGFR\<60, ESRD, neuropathy and retinopathy            N/A                      High
  NHS[@b46-pgpm-11-071]               2013   Nested case-- control           26/44                            59.8          0          Females with T2D           Nonfatal MI and fatal CHD                                          N/A                      High
  Bruneck study[@b47-pgpm-11-071]     2014   Nested case-- control           387/419                          63            48         T2D                        Incident fatal and nonfatal MI and stroke                          N/A                      High
  HPFS[@b48-pgpm-11-071]              2015   Nested case-- control           38/50                            63            100        Males with T2D             Nonfatal MI or fatal CHD                                           N/A                      High
  DCCT/EDIC[@b49-pgpm-11-071]         2016   Cohort                          516/787                          27            54         T1D                        CAD and MI                                                         N/A                      High

**Abbreviations:** CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study; DHS, Diabetes Heart Study; EDC, Epidemiology of Diabetes Complications; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HOPE, Heart Outcomes Prevention Evaluation; Hp, haptoglobin; HPFS, Health Professionals Follow-up Study; ICARE, Israeli Cardiovascular Vitamin E; MI, myocardial infarction; N/A, not available; NHS, Nurses' Health Study; PTCA, percutaneous transcatheter coronary angioplasty; RCT, randomized controlled trial; SHS, Strong Heart Study; T1D; type 1 diabetes mellitus; T2D; type 2 diabetes mellitus, TVR, target vessel revascularization; WHS, Women's Health Study.
